MAP2K7 and melanoma: Another clinical trial, IMspire150 evaluated atezolizumab (anti-PDL-1) with cobimetinib and vemurafenib (BRAF/MEK inhibitors) (triple therapy) on advanced, locally resectable melanoma patients.